I've traveled to the UK and Germany in the past year to present at conferences about what's happening on the pharmaceutical social media front here in the U.S. and its impact on pharmaceutical marketing elsewhere in the world.
My next trip to Europe will be to Milano
, Italy, where I will speak at the 6th Annual Pharma Marketing & Branding Excellence
conference on January 25.
The title of my presentation is "A Social Media Strategy: Deal with Regulations, Develop Best Practices." When I came up with that title, I was pretty sure the FDA would have issued some guidance on social media regulations before I would make my presentation. Now, however, it appears that there will be nothing that pharma needs to deal with in terms of complying with FDA's written regulatory guidance because there is none. So, the industry must continue to deal with a LACK of guidance. That's fine, because guidance or no guidance, best practices in social media communications is still evolving and there will be plenty for me to talk about. Read this entire OpEd piece here: